Shots:
- Biocon Biologics has launched Yesintek (ustekinumab- kfce), a biosimilar to Stelara, to treat psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric psoriatic arthritis across the US. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial
- The approval was supported by analytical, nonclinical & clinical data from a P-III (STELLAR-2) study of Yesafili vs Stelara in moderate-to-severe chronic Plaque Psoriasis, confirming its similarity in PK, safety, efficacy & immunogenicity
- YESINTEK will have commercial payor coverage at launch and a comprehensive patient assistance program, including benefits verification and copay support. Eligible patients may pay as little as $0, with a copay program competitive to the originator’s
Ref: Biocon Biologics | Image: Biocon Biologics
Related News:- Biocon Biologics Reports the US FDA’s Approval of Yesintek (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
